- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Di | Pharmas have promised $370B in US investments amid 2025's onshoring boom: DPR | ||
| Di | Regulatory tracker: Eisai finalizes FDA filing for subcutaneous Leqembi starter dose | ||
| Mo | FDA's Prasad tells staffers agency plans to get tougher on vaccine regulation, blames child deaths on COVID shots | ||
| Mo | Tanabe Pharma shifts gears for Bain-backed future, dropping Mitsubishi moniker after $3.3B deal | ||
| Mo | Microsize, Schedio link to buy Lonza's Swiss micronization plant | ||
| Mo | Close of Omnicom-Interpublic megamerger brings new health CEO, 4K layoffs | ||
| Mo | In UK trade deal, Trump administration excludes drugs from tariffs and secures promise of more pharma investment | ||
| Mo | Lilly lowers self-pay prices of single-dose Zepbound vials | ||
| 26.11. | Medicare unveils price reductions for 15 drugs, including Novo's semaglutide | ||
| 26.11. | Novo cashes in FDA national priority voucher for extra-speedy review of high-dose Wegovy | ||
| 26.11. | In crowded kidney disease space, Otsuka receives FDA approval for first-in-class Voyxact | ||
| 26.11. | French authorities raid Sanofi headquarters in tax fraud probe | ||
| 25.11. | Calling all rising stars in pharma marketing: Nominations open for Fierce feature series | ||
| 25.11. | Sarepta gets FDA's go-ahead to study immunosuppressive Elevidys regimen in bid to reverse label restriction | ||
| 25.11. | AbbVie short film showcases 'Second Winds' of life after CLL diagnosis | ||
| 25.11. | Pharma pros skeptical of letting AI loose on regulatory compliance submissions: survey | ||
| 25.11. | Lawmakers probe FDA's new priority voucher program, cite corruption and rushed review concerns | ||
| 25.11. | Novartis to cut 550 jobs at plant in Switzerland by end of 2027 | ||
| 25.11. | Novartis scores FDA approval for new version of SMA gene therapy, prices at $2.59M | ||
| 25.11. | Angelini faces UK marketing watchdog's wrath after speaker blasts 'stupid' EMA | ||
| 24.11. | SK Life Science Xcopri ad meets a roadblock with FDA untitled letter | ||
| 24.11. | Novo shares tumble after 2 trial misses for semaglutide in Alzheimer's disease | ||
| 24.11. | Merck's partner Kelun touts phase 3 win for ADC-Keytruda combo in first-line lung cancer | ||
| 21.11. | AstraZeneca boosts its presence in Maryland with $2B manufacturing investment | ||
| 21.11. | FDA grants game-changing perioperative approval to Padcev, Keytruda combo in bladder cancer |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .